Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Red Light and 0.01% Atropine for Myopia Prevention
NCT06727019Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of NVK002 in myopia (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Incidence of myopia at 12 months. Started Apr 2023; status: completed.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06727019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727019.